This study aimed to investigate the effectiveness of CoronaVac vaccine, which is more than 90% protective in healthy people, in cancer patients receiving active chemotherapy. In this study, to collect information to measure the amount of antibodies produced by the vaccine in the blood of volunteers with the CoronoVac vaccine and to compare it with healthy volunteers.
Study Type
OBSERVATIONAL
Enrollment
291
SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination
Tekirdağ Namık Kemal ÜNiversitesi
Tekirdağ, Turkey (Türkiye)
Antibody levels above the defined cut-off
SARS-CoV-2 IgG II ≥ 50.0 AU/ml (positive) and SARSCoV- 2 IgM \>1 (positive)
Time frame: Between the third and sixth weeks after the second dose of vaccine
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.